Knott David M Jr Purchases New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Knott David M Jr bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,000 shares of the company's stock, valued at approximately $479,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in Viridian Therapeutics by 11.1% in the fourth quarter. Geode Capital Management LLC now owns 1,658,980 shares of the company's stock valued at $31,809,000 after buying an additional 165,669 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Viridian Therapeutics by 3.8% in the 4th quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock valued at $43,842,000 after acquiring an additional 84,255 shares during the last quarter. Pictet Asset Management Holding SA raised its position in shares of Viridian Therapeutics by 21.8% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,248,721 shares of the company's stock worth $23,938,000 after acquiring an additional 223,384 shares in the last quarter. Loomis Sayles & Co. L P purchased a new stake in Viridian Therapeutics during the fourth quarter worth approximately $26,845,000. Finally, BIT Capital GmbH boosted its holdings in Viridian Therapeutics by 239.8% in the fourth quarter. BIT Capital GmbH now owns 285,954 shares of the company's stock valued at $5,482,000 after purchasing an additional 201,808 shares in the last quarter.

Analysts Set New Price Targets

VRDN has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Royal Bank of Canada boosted their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Viridian Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock traded down $0.66 during mid-day trading on Friday, reaching $11.99. 1,938,737 shares of the company were exchanged, compared to its average volume of 1,179,653. The firm has a market cap of $977.01 million, a PE ratio of -2.78 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm's 50-day simple moving average is $16.18 and its two-hundred day simple moving average is $19.43. Viridian Therapeutics, Inc. has a twelve month low of $11.31 and a twelve month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.